These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25170205)

  • 1. Selection criteria in resectable pancreatic cancer: a biological and morphological approach.
    Tamburrino D; Partelli S; Crippa S; Manzoni A; Maurizi A; Falconi M
    World J Gastroenterol; 2014 Aug; 20(32):11210-5. PubMed ID: 25170205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New challenges in perioperative management of pancreatic cancer.
    Puleo F; Maréchal R; Demetter P; Bali MA; Calomme A; Closset J; Bachet JB; Deviere J; Van Laethem JL
    World J Gastroenterol; 2015 Feb; 21(8):2281-93. PubMed ID: 25741134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
    Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
    J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
    Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
    Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of aggressive surgery for an invasive carcinoma derived from an intraductal papillary mucinous neoplasm diagnosed preoperatively as borderline resectable.
    Aimoto T; Mizutani S; Kawano Y; Suzuki H; Uchida E
    J Nippon Med Sch; 2013; 80(5):371-7. PubMed ID: 24189355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of survival after left-sided pancreatic resection for adenocarcinoma: Introduction of a new prognostic score.
    Gwiasda J; Qu Z; Schrem H; Oldhafer F; Winny M; Klempnauer J; Grannas G; Kaltenborn A
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):569-575. PubMed ID: 31279680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study.
    Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ
    J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
    Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
    Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decision making for pancreatic resection in patients with intraductal papillary mucinous neoplasms.
    Xu B; Ding WX; Jin DY; Wang DS; Lou WH
    World J Gastroenterol; 2013 Mar; 19(9):1451-7. PubMed ID: 23539521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
    Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
    Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the surgical waiting list affect pathological and survival outcome in resectable pancreatic ductal adenocarcinoma?
    Marchegiani G; Andrianello S; Perri G; Secchettin E; Maggino L; Malleo G; Bassi C; Salvia R
    HPB (Oxford); 2018 May; 20(5):411-417. PubMed ID: 29191689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer.
    Kim HW; Lee JC; Paik KH; Kang J; Kim YH; Yoon YS; Han HS; Kim J; Hwang JH
    Surgery; 2017 Jun; 161(6):1579-1587. PubMed ID: 28237643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial.
    Wittel UA; Lubgan D; Ghadimi M; Belyaev O; Uhl W; Bechstein WO; Grützmann R; Hohenberger WM; Schmid A; Jacobasch L; Croner RS; Reinacher-Schick A; Hopt UT; Pirkl A; Oettle H; Fietkau R; Golcher H
    BMC Cancer; 2019 Oct; 19(1):979. PubMed ID: 31640628
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased neutrophil-to-lymphocyte ratio after neoadjuvant therapy is associated with worse survival after resection of borderline resectable pancreatic ductal adenocarcinoma.
    Glazer ES; Rashid OM; Pimiento JM; Hodul PJ; Malafa MP
    Surgery; 2016 Nov; 160(5):1288-1293. PubMed ID: 27450715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study.
    Heinrich S; Besselink M; Moehler M; van Laethem JL; Ducreux M; Grimminger P; Mittler J; Lang H; Lutz MP; Lesurtel M;
    BMC Cancer; 2019 Jul; 19(1):675. PubMed ID: 31288786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
    Distler M; Pilarsky E; Kersting S; Grützmann R
    Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CA19-9 level determines therapeutic modality in pancreatic cancer patients with para-aortic lymph node metastasis.
    Asaoka T; Miyamoto A; Maeda S; Hama N; Tsujie M; Ikeda M; Sekimoto M; Nakamori S
    Hepatobiliary Pancreat Dis Int; 2018 Feb; 17(1):75-80. PubMed ID: 29428109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.